▲ +18.81% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Cansortium in the last 3 months. The average price target is $1.20, with a high forecast of $1.20 and a low forecast of $1.20. The average price target represents a 18.81% upside from the last price of $1.01.
The current consensus among 1 investment analysts is to buy stock in Cansortium.
Cansortium Inc., through its subsidiaries, produces and sells medical cannabis in the United States. It operates cultivation, processing, and dispensary facilities in Florida and Texas; and a dispensary license in Pennsylvania. The company offers its products in the form of oral drops, capsules, suppositories, topicals, syringes, dried flowers, prerolls, and cartridges. It markets its products under the Fluent brand name. As of December 21, 2020, it operated 24 dispensaries. Cansortium Inc. was founded in 2015 and is headquartered in Miami, Florida.